Monoclonal antibody for resisting novel coronavirus or derivative thereof

A monoclonal antibody, coronavirus technology, applied in the fields of cellular immunology and molecular biology, which can solve problems such as complex components

Active Publication Date: 2020-09-04
JIANGSU PROVINCIAL CENT FOR DISEASE CONTROL & PREVENTION PUBLIC HEALTH RES INST OF JIANGSU PROVINCE
View PDF3 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the complex composition of plasma and ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal antibody for resisting novel coronavirus or derivative thereof
  • Monoclonal antibody for resisting novel coronavirus or derivative thereof
  • Monoclonal antibody for resisting novel coronavirus or derivative thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1 Antibody Screening

[0058] 1. Phage library construction

[0059] 1. Collect peripheral blood from patients with COVID-19 during recovery period, and separate mononuclear cells (PBMC) from peripheral blood

[0060]In this project, on February 14, 2020, after informed consent, 20ml of peripheral blood was collected from 5 patients diagnosed with COVID-19 before discharge. The 5 patients were all non-severe cases in the same transmission chain. After treatment, they were discharged from the hospital and isolated at home from February 15th to 22nd. Mononuclear cells (PBMC) were isolated from 20 ml of heparin-anticoagulated blood by density gradient centrifugation using GE's Ficoll-Paque PLUS.

[0061] 2. RNA extraction and cDNA synthesis in PBMC

[0062] Use QIAGEN's RNeasy Mini Kit to extract PBMC cell RNA, and then use Roche's first strand synthesis kit (Transcriptor First Strand cDNA Synthesis Kit, Roche, Cat No.: 04896866001) to reverse transcribe the RNA...

Embodiment 2

[0105] Example 2 Indirect ELISA detection antibody binding specificity to S-RBD and S-ECD

[0106] Three human antibodies were selected from the 159 antibodies obtained through screening, and they were constructed into IgG-form human full-molecular antibodies (the three antibodies were named FC05, FC08, and FC11), expressed in 293F cells, and purified with Protein A Backup.

[0107] The FC08 antibody sequence is as follows:

[0108] The CDR1 sequence of the heavy chain variable region is shown in SEQ ID NO:1, the sequence of the CDR2 of the heavy chain variable region is shown in SEQ ID NO:2, and the CDR3 sequence of the heavy chain variable region is shown in SEQ ID NO:3; The CDR1 sequence of the light chain variable region is shown in SEQ ID NO:5, the CDR2 sequence of the light chain variable region is shown in SEQ ID NO:6, and the CDR3 sequence of the light chain variable region is shown in SEQ ID NO:7. The amino acid sequence of the heavy chain variable region is shown i...

Embodiment 3

[0113] Embodiment 3 Immunoprecipitation experiment of antibody, S-RBD and S-ECD

[0114] In the early stage, Western Blot was used to detect the binding specificity of the three antibodies to S-RBD and S-ECD, and it was found that none of the three antibodies reacted with S-RBD and S-ECD after SDS-PAGE, indicating that the three antibodies were all conformational epitope. Therefore, the immunoprecipitation (Immunoprecipitation, IP) method was used to detect the binding specificity of the antibody to the target protein, as follows:

[0115] Combine FC05, FC08 and FC11 triclonal antibodies with 20μL Protein A beads at room temperature for 2min, then wash away unbound antibodies with 20mM sodium phosphate. Then 20 μg of target antigens (S-RBD and S-ECD) were added to the antibody and Protein A gel mixture, and combined at room temperature for 2 minutes. Wash away the unbound antigen with 20mM sodium phosphate, elute the antigen-antibody complex with 30μl Gly-HCl buffer (pH 3.0)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Affinityaaaaaaaaaa
Login to view more

Abstract

The invention discloses a monoclonal antibody for resisting novel coronavirus or a derivative thereof. The monoclonal antibody comprises antigen complementary determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region, wherein the CDR1, the CDR2 and the CDR3 are amino acid sequences of SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7 respectively; the antigen complementary determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region are amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 respectively. The invention further discloses a preparation process of the antibody and amino acid sequences of the antibody heavy chain variable region and the antibody light chain variable region.

Description

technical field [0001] The invention belongs to the fields of cellular immunology and molecular biology, and relates to an anti-new coronavirus monoclonal antibody or a derivative thereof. Background technique [0002] The International Committee on Taxonomy of Viruses named the new coronavirus as SARS-CoV-2, and the World Health Organization named the pneumonia caused by this virus as COVID-19. The virus is highly contagious and spreads widely. The virus can quickly adapt to the human environment, and has the ability to spread during the incubation period after infection. At the same time, some asymptomatic infections have been reported, and viral nucleic acids have even been detected in various animals. These factors make the prevention and control of the virus very complicated, and there are currently no effective therapeutic drugs and vaccines on the market. [0003] SARS-CoV-2 belongs to the genus Coronaviridae and is a single-stranded positive-sense RNA virus with a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/10C12N15/13C12N15/70G01N33/569G01N33/577A61K39/42A61P31/14
CPCA61P31/14C07K16/10C07K2317/33C07K2317/55C07K2317/565C07K2317/76C07K2317/92C12N15/70G01N33/56983G01N33/577
Inventor 朱凤才张黎高行素郑滨洋郭喜玲陈银王祥喜李靖欣
Owner JIANGSU PROVINCIAL CENT FOR DISEASE CONTROL & PREVENTION PUBLIC HEALTH RES INST OF JIANGSU PROVINCE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap